Merck Calls It Quits On Anacetrapib
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
You may also be interested in...
Positive Phase II data indicate that obicetrapib, a cholesterol-lowering drug licensed from Amgen, could succeed where prior drugs in the class have consistently failed for more than a decade.
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.